#Denmark #Lundbeck #bexicaserin #Valby #DEEp Program

Lundbeck’s Breakthrough Insights on Bexicaserin at European Epilepsy Congress

Lundbeck, a leading biopharmaceutical company, draws attention with exciting revelations about bexicaserin, a novel treatment under investigation for seizures related to developmental and epileptic encephalopathies (DEEs). The upcoming European Epilepsy Congress in Athens, taking place from September 5-9, 2026, will showcase Lundbeck's latest preclinical and clinical data that emphasizes the dual mode of action of bexicaserin.

This innovative compound is notable for its role as a highly-selective superagonist of the 5-HT2c receptor, which has been linked to a promising mechanism of increasing inhibitory and decreasing excitatory neuronal activities. In preclinical studies, researchers have unearthed insights suggesting that this dual mechanism could provide broad-spectrum antiseizure activity across a variety of seizure types, including focal, generalized motor, and absence seizures resulting from different underlying causes.

Understanding Developmental and Epileptic Encephalopathies (DEEs)

DEEs represent a heterogeneous group of severe neurological disorders that typically impact young children. These disorders are marked by frequent and treatment-resistant seizures, abnormal electroencephalogram (EEG) activities, and often a plateau or regression in developmental milestones. The various syndromes classified under DEEs include notorious conditions like Lennox-Gastaut syndrome and Dravet syndrome, with differing genetic and environmental etiologies contributing to their complexity. The necessity for innovative treatment options is evident, given that no current antiseizure medications effectively target all types of DEEs.

Presentation Highlights at the Congress

Lundbeck's presentations at the congress will encompass several fascinating studies:

• - Oral Presentation: An in-depth discussion on how bexicaserin exerts antiseizure effects through its modulation of neuronal functions, enabling increased inhibition while decreasing excitatory signals, expected to provide new pathways to manage DEEs effectively.
• - Poster Presentations: These will cover various aspects of bexicaserin's effects, including an expanded access program with participants on treatment for up to two years and analyses of seizure response over time in different clinical scenarios.

Tarek Samad, Lundbeck's Executive VP, expresses confidence in bexicaserin’s potential, stating that the data presented will underscore the strong scientific rationale for its dual mode of action in addressing the high unmet needs within DEEs. The evidence gathered forms a compelling case for advancing bexicaserin's ongoing global Phase III DEEp Program, aimed at evaluating its efficacy and safety in diverse populations affected by these challenging conditions.

Broader Context and Future Directions

As DEEs often manifest with exacerbated seizure activity due to network hyperexcitability, the preliminary data surrounding bexicaserin reinforces its promising application in potentially mitigating these harsh symptoms. Lundbeck, demonstrating an unwavering commitment to neuroscience, aims to deepen its understanding of bexicaserin's mechanisms to further enhance treatment paradigms not just for DEEs but for related epileptic conditions as well.

The DEEp Program includes trials specifically targeting children and adults with significant conditions such as Lennox-Gastaut and Dravet syndromes both of which demand immediate therapeutic advances. The FDA has already acknowledged the potential of bexicaserin by granting it a Breakthrough Therapy designation, which highlights its significance in changing the treatment landscape for DEEs.

Conclusion

Lundbeck's research initiatives reflect a commitment to improving the lives of those grappling with severe neurological challenges. With the unveiling of data at the European Epilepsy Congress, the hopes for bexicaserin to address unmet medical needs in treating DEEs might soon pave the way for transformative changes in care for patients worldwide. The presentation of both clinical and preclinical insights at this significant gathering is anticipated to spur further interest and critical dialogue around innovative therapies in this domain.